A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose[1]Ranging Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Patients with Mycobacterium avium Complex (MAC) Pulmonary Disease
Phase: 2
Status: Ongoing
Details
The purpose of this study is to learn how well the study drug works compared with
placebo; how safe and tolerable the study drug is compared with placebo; and to check
the amount of study drug in the body.
Sponsor: Spero Therapeutics, Inc.
NCT05496374 - IRB#2023-024